Screening M1PAMs Using Alpha Value to Reduce Cholinergic Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cholinergic muscarinic M1 receptor positive allosteric modulators (M1PAMs) often cause cholinergic side effects such as diarrhea, and there is a need for an efficient screening method to identify M1PAMs with reduced side effects for treating Alzheimer's disease and other conditions.
Innovation Solution
A method for screening M1PAMs with reduced cholinergic side effects using the α-value as an index, which involves evaluating the binding cooperativity between the M1PAM and acetylcholine. This method also includes a combination therapy of M1PAMs with low α-values and acetylcholinesterase inhibitors for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If M1PAMs are used to treat Alzheimer's disease and enhance cognitive function, then therapeutic effects are improved, but cholinergic side effects such as diarrhea occur
Solution Approach 1:
The patent applies parameter changes by introducing the α-value as a new screening parameter to identify M1PAMs with reduced cholinergic side effects. By changing the selection criterion from general M1PAM activity to specific α-value thresholds, the patent resolves the contradiction between therapeutic efficacy and side effect profile.
Solution Approach 2:
The patent applies local quality by differentiating between M1PAMs based on their specific α-values. Instead of treating all M1PAMs uniformly, the patent identifies and selects compounds with low α-values (≤1000, preferably ≤500) that specifically reduce cholinergic side effects while maintaining cognitive benefits.
2Ease of manufacture
If traditional screening methods are used to identify M1PAMs, then compound discovery is simplified, but side effects cannot be predicted
Solution Approach 1:
The patent applies preliminary action by performing α-value calculation during the early screening phase of compound identification. This allows side effect prediction to occur before compound development proceeds, enabling early filtering of compounds with high cholinergic side effect risk.
Solution Approach 2:
The patent introduces the α-value as an intermediary parameter that connects M1PAM compound structure to cholinergic side effect prediction. This intermediary enables indirect prediction of side effects through a measurable parameter that can be calculated from binding data.
3Reliability
If M1PAMs with high activity are selected to maximize cognitive benefits, then therapeutic outcomes are enhanced, but cholinergic side effects increase
Solution Approach 1:
The patent changes the selection parameter from general M1PAM activity to the specific α-value parameter. By setting thresholds (α-value ≤1000, preferably ≤500), the patent identifies compounds that maintain cognitive benefits while reducing cholinergic side effects through optimized parameter selection.
Data Source
AI summary
The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.